Structure Therapeutics Inc ADR (GPCR)

Currency in USD
34.78
-0.33(-0.93%)
Real-time Data·
Advertisement
GPCR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
34.5735.63
52 wk Range
22.7094.90
Key Statistics
Prev. Close
35.1
Open
35.04
Day's Range
34.57-35.63
52 wk Range
22.7-94.9
Volume
136.54K
Average Volume (3m)
812.47K
1-Year Change
49.6771%
Book Value / Share
19.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GPCR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
105.78
Upside
+204.15%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

15 Buy
1 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 105.78
(+204.15% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy70.00+101.67%-Maintain09/09/2026
Citizens
Buy110.00+216.91%-Maintain09/09/2026
Jefferies
Buy125.00+260.13%-Maintain08/09/2026
Citizens
Buy110.00+216.91%113.00Maintain07/08/2026
H.C. Wainwright
Buy70.00+101.67%100.00Maintain11/06/2026

Structure Therapeutics Inc ADR SWOT Analysis


Oral GLP-1 Pionee
Structure Therapeutics leads the charge in developing oral treatments for diabetes and obesity, with aleniglipron showing promise in the competitive GLP-1 market
Pipeline Potential
Explore GPCR's robust pipeline, including aleniglipron and ACCG-2671, poised to disrupt the metabolic disease treatment landscape with oral formulations
Market Dynamics
Delve into Structure Therapeutics' strategic positioning amidst fierce competition from pharma giants, leveraging its focus on oral small molecule therapies
Financial Outlook
Analyst price targets range from $37.50 to $120 per share, reflecting optimism about GPCR's potential in the expanding GLP-1 receptor agonist market
Read full SWOT analysis

Earnings

Latest Release
06/08/2026
EPS / Forecast
-0.49 / -0.37
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare GPCR to Peers and Sector

Metrics to compare
GPCR
Peers
Sector
Relationship
P/E Ratio
−11.5x−7.1x−0.4x
PEG Ratio
3.66−0.040.00
Price/Book
1.8x2.5x2.6x
Price / LTM Sales
-12.4x3.0x
Upside (Analyst Target)
201.4%44.4%55.0%
Fair Value Upside
Unlock−1.3%7.6%Unlock

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
25.17M35.30%893.55M
Other Institutional Investors
58.75M64.70%2.09B
Public Companies & Retail Investors
0.000.00%0.00
Total
83.92M100.00%2.98B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC10.90%7,775,399276,027
Deep Track Capital, LP10.59%7,550,331268,037

People Also Watch

34.05
VERA
-0.64%
21.865
NAMS
-0.30%
19.15
RLAY
-0.23%
5.190
IRD
-1.70%
40.13
XENE
-30.03%

FAQ

What Is the Structure Therapeutics ADR (NASDAQ: GPCR) Share Price Today?

The Structure Therapeutics ADR stock price today is 34.78 USD.

What Stock Exchange Does Structure Therapeutics ADR (GPCR) Trade On?

Structure Therapeutics ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Structure Therapeutics ADR?

The stock symbol (also called a 'ticker') for Structure Therapeutics ADR is "GPCR."

What Is the Current Structure Therapeutics ADR Market Capitalisation?

As of today, Structure Therapeutics ADR (NASDAQ: GPCR) market cap is 2.50B USD.

What Is Structure Therapeutics ADR's (GPCR) Earnings Per Share (TTM)?

The Structure Therapeutics ADR EPS is currently -3.22 (Trailing Twelve Months).

When Is the Next Structure Therapeutics ADR Earnings Date?

Structure Therapeutics ADR's next earnings report will be released on 18/11/2026.

Is GPCR a Buy or Sell From a Technical Analyst Perspective?

Based on today's Structure Therapeutics ADR moving averages and other technical indicators, the daily buy/sell signal for GPCR stock is Strong Sell.

How Many Times Has Structure Therapeutics ADR Stock Split?

Structure Therapeutics ADR has split 0 times. (See the GPCR stock split history page for full effective split date and price information.)

How Many Employees Does Structure Therapeutics ADR Have?

Structure Therapeutics ADR has 281 employees, based on their latest Companies House report.

What is the current trading status of Structure Therapeutics ADR (NASDAQ: GPCR)?

As of 18/09/2026, Structure Therapeutics ADR (GPCR) is trading at a share price of 34.78 USD, with a previous close of 35.10 USD. The stock has fluctuated within a day range of 34.57 USD to 35.63 USD, while its 52-week range spans from 22.70 USD to 94.90 USD.

What Is Structure Therapeutics ADR (GPCR) Price Target According to Analysts?

The average 12-month price target for Structure Therapeutics ADR is 105.78 USD, with a high estimate of 145 USD and a low estimate of 70 USD. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +204.15% Upside potential.

What Is the GPCR Premarket Price?

GPCR's last pre-market stock price is 35.00 USD. The pre-market share volume is 2,430.00, and the stock has decreased by -0.10, or -0.28%.

What Is the GPCR After Hours Price?

GPCR's last after hours stock price is 35.15 USD, the stock has decreased by 0.05, or 0.14%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.